Oncology Institute’s (TOI) Buy Rating Reaffirmed at BTIG Research

Oncology Institute (NASDAQ:TOI)‘s stock had its “buy” rating restated by analysts at BTIG Research in a report issued on Monday,Benzinga reports. They currently have a $7.00 price objective on the stock. BTIG Research’s target price would suggest a potential upside of 151.80% from the company’s previous close.

TOI has been the topic of a number of other research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oncology Institute in a report on Wednesday, January 21st. Needham & Company LLC reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Oncology Institute in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $6.50.

Oncology Institute Stock Performance

NASDAQ:TOI opened at $2.78 on Monday. The firm has a market cap of $273.50 million, a P/E ratio of -4.34 and a beta of 0.14. Oncology Institute has a fifty-two week low of $0.60 and a fifty-two week high of $4.88. The firm has a 50-day simple moving average of $3.10 and a two-hundred day simple moving average of $3.42.

Insider Buying and Selling at Oncology Institute

In other news, Director Brad Hively sold 13,333 shares of the stock in a transaction on Monday, December 15th. The stock was sold at an average price of $3.77, for a total transaction of $50,265.41. Following the transaction, the director directly owned 683,721 shares of the company’s stock, valued at $2,577,628.17. This represents a 1.91% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 8.50% of the stock is owned by insiders.

Institutional Trading of Oncology Institute

Large investors have recently modified their holdings of the company. ProShare Advisors LLC purchased a new stake in Oncology Institute during the second quarter valued at $25,000. Kestra Advisory Services LLC purchased a new position in Oncology Institute in the fourth quarter worth about $31,000. Police & Firemen s Retirement System of New Jersey purchased a new position in Oncology Institute in the second quarter worth about $32,000. Pekin Hardy Strauss Inc. bought a new stake in shares of Oncology Institute during the 4th quarter valued at about $36,000. Finally, Cetera Investment Advisers increased its position in shares of Oncology Institute by 35.0% during the 2nd quarter. Cetera Investment Advisers now owns 17,545 shares of the company’s stock valued at $36,000 after purchasing an additional 4,545 shares during the last quarter. Institutional investors own 36.86% of the company’s stock.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.